These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14601057)

  • 1. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
    Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
    Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
    Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
    Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
    Mehrotra J; Vali M; McVeigh M; Kominsky SL; Fackler MJ; Lahti-Domenici J; Polyak K; Sacchi N; Garrett-Mayer E; Argani P; Sukumar S
    Clin Cancer Res; 2004 May; 10(9):3104-9. PubMed ID: 15131050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
    Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
    Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
    Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation biomarkers for pleomorphic lobular breast cancer - a short report.
    Moelans CB; Vlug EJ; Ercan C; Bult P; Buerger H; Cserni G; van Diest PJ; Derksen PW
    Cell Oncol (Dordr); 2015 Oct; 38(5):397-405. PubMed ID: 26392358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
    Verschuur-Maes AH; de Bruin PC; van Diest PJ
    Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
    Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
    Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
    Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
    BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
    Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
    Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
    Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
    Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.
    Lee JS; Fackler MJ; Teo WW; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Argani P; Sukumar S
    Cancer Biol Ther; 2008 Sep; 7(9):1398-406. PubMed ID: 18769130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
    Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
    Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype.
    Lehmann U; Celikkaya G; Hasemeier B; Länger F; Kreipe H
    Cancer Res; 2002 Nov; 62(22):6634-8. PubMed ID: 12438260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction.
    Nayar R; Zhuang Z; Merino MJ; Silverberg SG
    Hum Pathol; 1997 Mar; 28(3):277-82. PubMed ID: 9042790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.